Due to the EGFR mutations in NSCLC, it is becoming resistant to Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and recent studies indicated that the LXR activation inhibits lung cancer proliferation and metastasis and also shows synergistic effect when combined with EGFR-TKIs (Liu et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.